DR. MICHAEL HUTCHINSON, MD
Neurology at 37 St, New York, NY
License number
New York 196868
Category
Neurology
Type
Diagnostic Neuroimaging
License number
New York 196868
Category
Neurology
Type
Neuromuscular Medicine
License number
New York 196868
Category
Neurology
Type
Neurology
Address
Address
345 E 37Th St SUITE 320, New York, NY 10016
Phone
(212) 889-2500
(855) 850-7848 (Fax)
(855) 850-7848 (Fax)
Personal information
See more information about MICHAEL HUTCHINSON at radaris.comName
Address
Phone
5140 Glenwood Dr, Buffalo, NY 14221
4826 Wilder Ave, Bronx, NY 10470
4 Bryan St, Saratoga Spgs, NY 12866
4988 Elgin Cir, Syracuse, NY 13215
5424 152Nd St #2, Flushing, NY 11355
Organization information
See more information about MICHAEL HUTCHINSON at bizstanding.comMichael Hutchinson MD
222 E 31 St, New York, NY 10016
Industry:
Radiology, Neurologist
Phone:
(212) 889-2500 (Phone), (212) 263-6618 (Phone)
Michael Hutchinson
Categories:
Neurology Physicians & Surgeons, Physicians & Surgeons
Professional information
Financial Services Manager At City Of New - Dept. Of Information Technology &Amp; Telecommunications
Position:
Financial Services Manager at City of New York - Dept. of Information Technology & Telecommunications
Location:
Greater New York City Area
Industry:
Information Technology and Services
Work:
City of New York - Dept. of Information Technology & Telecommunications
since Mar 2003
-
Financial Services Manager
Michael DR Hutchinson, New York NY
Specialties:
Neurology, Radiology
Work:
Schwartz Health Care Center
530 1St Ave, New York, NY 10016 NYU Hospitals Center
550 1St Ave, New York, NY 10016 Prince & Rutgers Neurology
51 Veronica Ave, Somerset, NJ 08873
530 1St Ave, New York, NY 10016 NYU Hospitals Center
550 1St Ave, New York, NY 10016 Prince & Rutgers Neurology
51 Veronica Ave, Somerset, NJ 08873
Education:
University of Miami(1988)
Deputy General Counsel, Stryker Corporation
Position:
Chief Legal Counsel, Orthopaedics & Spine at Stryker
Location:
Greater New York City Area
Industry:
Medical Devices
Work:
Stryker
since Jun 2008
-
Chief Legal Counsel, Orthopaedics & Spine
Dr. Michael Hutchinson, New York NY - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Neurology)
Address:
Michael Hutchinson MD
222 E 31St St SUITE 1R, New York 10016
(212) 889-2500 (Phone)
222 E 31St St SUITE 1R, New York 10016
(212) 889-2500 (Phone)
Certifications:
Neurology, 1994
Awards:
Healthgrades Honor Roll
Languages:
English, French
Hospitals:
Michael Hutchinson MD
222 E 31St St SUITE 1R, New York 10016
NYU Langone Medical Center
550 1St Ave, New York 10016
222 E 31St St SUITE 1R, New York 10016
NYU Langone Medical Center
550 1St Ave, New York 10016
Education:
Medical School
University of Miami / School of Medicine
Graduated: 1988
Hahnemann University Hospital
University Hospital
UCLA Med Ctr
University of Miami / School of Medicine
Graduated: 1988
Hahnemann University Hospital
University Hospital
UCLA Med Ctr
Indirect Delivery Of Growth Factors Into The Central Nervous System
US Patent:
2005004, Mar 3, 2005
Filed:
Aug 26, 2004
Appl. No.:
10/927301
Inventors:
Michael Hutchinson - New York NY, US
John Gianutsos - New York NY, US
John Gianutsos - New York NY, US
International Classification:
A61K038/18
US Classification:
514012000
Abstract:
The present invention provides a method of delivering a treatment to the central nervous system, including the steps of administering a therapeutic intramuscularly into muscles innervated by nerves chosen from the group consisting of cranial nerves and spinal nerves, and transporting the therapeutic peripherally through nerves into the CNS and to the site of treatment. The present invention provides a method of treating a neural disorder or a part of the body by administering an effective amount of a compound affecting neural cells into muscles innervated by cranial and/or spinal nerves, and affecting neural cells. The present invention also provides a method of treating a spinal cord injury by administering an effective amount of a compound affecting neural cells into musculature directly innervated by the spinal cord, and affecting neural cells. The present invention further provides a method of treating Parkinson's disease by administering an effective amount of a compound affecting neural cells into musculature innervated by the motor trigeminal nerve, and affecting neural cells involved in Parkinson's disease. Finally, the present invention also provides a method of treating amyotrophic lateral sclerosis by administering an effective amount of a compound affecting neural cells into musculature innervated by cranial and/or spinal nerves, and affecting neural cells involved in amyotrophic lateral sclerosis.
Mri Detection And Staging Of Parkinson's Disease And Detection Of Progressive Supranuclear Palsy
US Patent:
7613495, Nov 3, 2009
Filed:
Nov 30, 2001
Appl. No.:
09/997894
Inventors:
Michael Hutchinson - New York NY, US
Assignee:
Advanced MRI Technologies, LLC - Sebastopol CA
International Classification:
A61B 5/055
US Classification:
600410
Abstract:
A method of detecting Parkinson's disease through MRI of substantial nigra pars compacta (SNc) tissue. The method involves obtaining a gray matter suppressed (GMS) MRI signal from the SNc tissue, obtaining a white matter suppressed (WMS) MRI signal of the SNc tissue, and combining information from the GMS and WMS MRI signals to produce resultant signals indicative of Parkinson's disease. A similar method can be used to detect Progressive Supranuclear Palsy. A method of distinguishing between the two diseases involves obtaining at least two starting MRI images of SNc tissue using different MRI parameters, and combining the starting images to compute resultant signals differentiating between the two forms of parkinsonism.
Cholinesterase Inhibitors For Treatment Of Parkinson's Disease
US Patent:
5965571, Oct 12, 1999
Filed:
Aug 21, 1997
Appl. No.:
8/915736
Inventors:
Michael Hutchinson - New York NY
Assignee:
New York University - New York NY
International Classification:
A01N 4344
US Classification:
514297
Abstract:
Parkinson's disease can be treated with an at least one cholinesterase inhibitor. The cholinesterase inhibitor has been found to alleviate both any symptoms of dementia as well as to reduce rigidity and improve motor function.